ClinConnect ClinConnect Logo
Search / Trial NCT06762002

Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 6, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Covid 19 Auto Immunity Type I Interferon Kinetics Infectious Diseases

ClinConnect Summary

This clinical trial is looking at how certain genetic factors and antibodies can affect people’s immune response, especially to infections like COVID-19. Researchers have found that some individuals with severe COVID-19 disease have a genetic condition that impacts their immune system or have antibodies that hinder their ability to respond to infections. The goal of this study is to follow a group of adults who either have these antibodies or genetic issues for 1 to 4 years. By monitoring their health over time, the researchers hope to learn more about how to prevent and treat infections and autoimmune diseases in these individuals.

To participate, applicants need to be over 18 years old and have a history of either having antibodies against type I interferons (a part of the immune response) or a genetic defect affecting this response. Participants will attend annual check-ups, where they will provide blood samples and answer questions about their health. If they experience any health issues, such as infections or new autoimmune diseases, they will have additional visits to monitor their condition. Participants will also be offered vaccines for COVID-19 and influenza. Overall, this study aims to gain valuable insights into the immune system and improve care for those affected.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \>18 years
  • History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI)
  • Affiliated to social security
  • Written informed consent
  • Exclusion Criteria:
  • Participation to an interventional clinical trial on a pharmacological treatment
  • Clinical condition leading to life expectancy less than 1 year
  • Subject to a legal protection measure (safeguard of justice, curatorship, tutorship)
  • Individuals deprived of freedom

About Institut National De La Santé Et De La Recherche Médicale, France

The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.

Locations

Lille, , France

Lyon, , France

Montpellier, , France

Paris, , France

Paris, , France

Paris, , France

Paris, , France

Paris, , France

Tours, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported